Dermata reports statistically significant Phase 3 XYNGARI acne data vs placebo at EADV 2025

Dermata Therapeutics, Inc.

IGA 2-point reduction + clear/almost clear at Week 12: 29.4% XYNGARI vs 15.2% placebo (p<0.001).
Mean inflammatory lesion count change at Week 12: -16.8 XYNGARI vs -13.1 placebo (p<0.001).
Percent change in non-inflammatory lesions at Week 12: 48.3% XYNGARI vs 34.7% placebo (p<0.001).
All secondary endpoints (IGA, inflammatory, non-inflammatory) statistically significant at Weeks 4, 8, and 12.
Data presented at European Academy of Dermatology and Venereology Congress 2025 from ongoing Phase 3 STAR-1 trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.